MP
SEEL

Mangrove Partners’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Mangrove Partners’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-556
Closed -$3.48M – 505
2021
Q4 		$3.48M Hold
556
– – 0.21% 167
2021
Q3 		$5.14M Hold
556
– – 0.46% 41
2021
Q2 		$5.63M Sell
556
-7
-1% -$115K 0.58% 34
2021
Q1 		$10.8M Buy
+563
New +$6.57M 1.09% 10

Other funds holding SEEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Mangrove Partners's SEEL Position: Q1 2022 in Review

Mangrove Partners sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2022, closing a stake of 556 shares — an estimated $3.48M sold.

Mangrove Partners first reported a position in SEEL in Q1 2021 and held it in 4 quarters. The position peaked at $10.8M in Q1 2021. 77 funds tracked by Wall St. Rank hold SEEL as of Q1 2022.

  • Mangrove Partners reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Mangrove Partners sold 556 Seelos Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $3.48M.
  • Mangrove Partners first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • Mangrove Partners's Seelos Therapeutics, Inc. Common Stock position peaked at $10.8M in Q1 2021.
  • 77 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Mangrove Partners's 13F filing for Q1 2022, filed 16 May 2022.